{"disease":{"id":"malignant-pleural-mesotheliomas","name":"malignant pleural mesotheliomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00242723","title":"Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining","phase":"","overall_status":"RECRUITING","enrollment_count":1310,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05278975","title":"Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"RS Oncology LLC","has_results":false},{"nct_id":"NCT07510815","title":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT03233724","title":"Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05375825","title":"Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}